Chris Dunsby

Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Time-lapse imaging of representative AKTP MTO organoids from vehicle and RMC-9945 treatment conditions. Initial imaging (time 0h) was performed prior to vehicle or RMC-9945 treatment. Upon treatment, organoids were imaged every hour over a 48-hour period. Top (vehicle) and bottom (RMC-9945) panels show XY planes positioned at three z-depths relative to the centre of the organoids volume (-10 µm, 0 µm and +10 µm). Lgr5-EGFP is shown in green and Emp1-TOM in red. Scale bar, 50 µm.

Year:

2026

Supplementary Figures S1-S14 related to the manuscript "A plastic EMP1 + to LGR5 + cell state conversion as a bypass to KRAS-G12D pharmacological inhibition in metastatic colorectal cancer"

Year:

2026

Dependency on Lgr5 + CSCs in RMC-9945–treated metastases. A, Relative mRNA expression of Gfp and Lgr5 genes in sorted GFP-high, -medium, -low, and -negative population from AKTP MTO-derived liver metastases. Mean ± SEM. B, Schematics of in vivo RMC-9945 treatment (7 days, starting at day 21 after implantation), Diphtheria toxin (DT) treatment (one injection any other day), or combination of RMC-9945 and DT, of liver metastases implanted in the spleen of C57BL/6J mice. C, Representative histograms of Lgr5 -EGFP expression of the EPCAM + /CD45 − population in mice treated with vehicle, RMC-9945, DT, and RMC-9945 + DT obtained by flow cytometry. D, Representative pictures of livers after 7 days of treatment with vehicle, RMC-9945, DT, and RMC-9945 + DT. Arrows pointing at liver metastases. E and F, Quantifications of total number of metastases per mouse in each condition described ( E ) and of the proportion of metastases per size (higher diameter; F ). Vehicle n = 5 mice, RMC-9945 n = 10, DT n = 8, and RMC-9945 + DT = 7. Mean ± SEM. For E, P values are derived from ANOVA followed by Tukey tests. For F , P values are derived from the β-binomial regression model. G, Schematics of in vivo RMC-9945 treatment (10 days, starting at day 15 after implantation), DT treatment (one injection every day), or combination of RMC-9945 and DT, of liver metastases implanted in the spleen of C57BL/6J mice. H and I, Quantifications of total number of metastases per mouse in each condition described ( H ) and of the proportion of metastases per size (higher diameter; I ). Vehicle n = 8 mice, RMC-9945 n = 12, DT n = 8, and RMC-9945 + DT = 12. Mean ± SEM. For H, P values are derived from ANOVA followed by Dunnett tests. For I , P values are derived from the β-binomial regression model. J, Representative pictures of livers after 10 days of treatment with vehicle, RMC-9945, DT, and RMC-9945 + DT. Arrows pointing at liver metastases. K, Kaplan–Meier survival plot of mice treated with the indicated treatments. P values are derived from Gehan–Breslow–Wilcoxon test.

Year:

2026

Time-lapse imaging of representative AKTP MTO organoids from vehicle and RMC-9945 treatment conditions. Initial imaging (time 0h) was performed prior to vehicle or RMC-9945 treatment. Upon treatment, organoids were imaged every hour over a 48-hour period. Top (vehicle) and bottom (RMC-9945) panels show XY planes positioned at three z-depths relative to the centre of the organoids volume (-10 µm, 0 µm and +10 µm). Lgr5-EGFP is shown in green and Emp1-TOM in red. Scale bar, 50 µm.

Year:

2026

Analysis of chromatin regulation by RMC-9945. A, Heatmaps and ATAC profile plots of differential peaks for vehicle-treated ( n = 4,148) and RMC-9945–treated ( n = 898) AKTP MTOs for 48 hours. B, Motif analysis on differential peaks reveals enrichment in members of the JUN/FOS family of TFs for vehicle (left) and LEF/TCF7 family of TFs for RMC-9945 (right). Top 30 significant most enriched motifs are shown. C, Representation (Gaudí plot) for ATAC-seq signal rendered for both the vehicle (left) and RMC-9945 (right), centered at chr6:134,835,000-135,835,000. Emp1 locus highlighted (green dot). All genomic bins within the dashed circle are taken into consideration for the motif search analysis. D, ChromBPNet contribution tracks for vehicle and RMC-9945 highlighting three (of six) AP1 motifs open in vehicle and closed in RMC-9945. Arcs represent the interaction between the TSS containing 5 kbp bin and those in spatial proximity in the Gaudí plot (dashed circle in C ). E, Gaudí plot for ATAC-seq signal rendered for Lgr5 locus, centered at chr10:114,920,000-115,925,000. Same representation as in C . F, ChromBPNet contribution and interaction tracks for vehicle and RMC-9945 highlighting four (of five) TCF7/LEF1 TF-binding sites open in RMC-9945.

Year:

2026

Inhibitors of the oncogene KRAS hold promise for treating metastatic colorectal cancer (mCRC). In this study, we show that a selective, covalent small-molecule inhibitor of the active (ON) conformation of RAS-G12D, RMC-9945, exerts durable disease control in preclinical colorectal cancer models of early liver metastasis, but its therapeutic activity was diminished in the advanced metastatic disease. RMC-9945–treated metastases underwent a transition from a poor prognosis–associated Emp1 + transcriptional state to a WNT-driven Lgr5 + stem cell–like state that withstands the absence of RAS-G12D activity. This cell state change occurred within hours of RAS(ON) inhibitor treatment through a shift in transcription factor usage that involved limited chromatin remodeling. Forced conversion of metastatic cells to the Lgr5 + state through RAS-G12D inhibition, followed by genetic ablation of this population, reduced metastatic burden and prolonged survival in a mouse mCRC model. Overall, these preclinical findings demonstrate a central role for oncogenic KRAS in governing cellular plasticity in mCRC. Significance: We show that inhibition of oncogenic KRAS in preclinical models of advanced mCRC exerts a limited benefit, primarily due to the reversion of tumor cells to a stem cell–like state. Our findings highlight the context-dependent effects of oncogenic KRAS mutations and underscore cell plasticity as a therapeutic opportunity. See related commentary by Eng and Yilmaz et al., p. 201

Year:

2026

RMC-9945 increases β-catenin/TCF transcriptional activity. A, Schematic representation of seven TCF optimal promoter (TOP) luciferase reporter lentiviral vector introduced into AKTP MTOs. TOP-Luciferase quantification of AKTP TOP-Luciferase MTOs, normalized to CellTiter-Glo parallel wells treated with vehicle or RMC-9945 for 1, 2, and 3 days ( n = 6). Linear mixed-effect model followed by EMMs with pairwise comparisons. B, Schematic of in vitro AKTP MTOs treated with vehicle or RMC-9945 for 48 hours, with media refresh at 12 hours. C, Immunofluorescence image quantification of the percentage of nuclear (4′,6-Diamidino-2-phenylindole, DAPI-positive) β-catenin–positive cells within AKTP MTO vehicle-treated or RMC-9945–treated organoids. D, Representative images of the quantification displayed in C . Dashed circles illustrate nuclear β-catenin–positive cells. Scale bars: 20 µm. P value is derived from unpaired t test. E, Experimental setup of RMC-9945 treatment of liver metastases. Treatment started at day 21 after inoculation of liver metastases implanted in the spleen of C57BL/6J mice and continued for 11 days. D and F, Immunofluorescence representative images ( F ), and quantification ( G ) of the percentage of nuclear (DAPI-positive) β-catenin–positive cells within liver metastasis derived from AKTP MTOs, treated with vehicle or RMC-9945. Scale bar, 100 µm top, 20 µm bottom. White arrows highlight examples of nuclear β-catenin–positive cells. P value is derived from unpaired t test. H, Heatmap showing expression of TFs in AKTP MTO organoids treated with vehicle or RMC-9945. I, Violin plots showing single-cell expression levels of WNT-related TFs in liver metastases treated with vehicle or RMC-9945. J, Schematic representation of the nTCF4-ERT2 construct which translocates into the nucleus and conditionally induces a WNT-OFF state upon treatment with 4-OH-tamoxifen. K, Schematic representation of the experiments displayed in L and M, consisting on nTCF4-ERT2 infected AKTP MTOs treated with 4-OH-tamoxifen in the corresponding conditions since 1 day after being seeded (day -2) and with RMC-9945 or vehicle for 7 days. L, Relative mRNA expression of indicated marker genes in vehicle-treated and RMC-9945–treated (with or without 4OHT) AKTP MTOs for 48 hours. Mean ± SEM. P values are derived from ANOVA followed by Šídák multiple comparisons test. M, AKTP MTO organoid growth (normalized bioluminescence) treated with vehicle, RMC-9945, 4-OH-tamoxifen + vehicle, or 4-OH-tamoxifen + RMC-9945. 4-OH-tamoxifen conditions are normalized to the mean luminescence of 4-OH-tamoxifen treatment at experimental day 0 and non–4-OH-tamoxifen–treated conditions are normalized to the mean luminescence of non–4-OH-tamoxifen treatment experimental day 0. Mean ± SEM; P values are derived from ANOVA followed by Šídák multiple comparisons test.

Year:

2026

PDAC and keratinization gene programs induced by KRAS activating mutations. A, Dot plot illustrating the scaled and normalized expression of selected marker genes across the different metastasis cell clusters (Louvain clustering, resolution = 0.6, SCT values). B, UMAP visualization showing PDAC basal cells ( B ) and epidermal keratinization ( C ) with black indicating the top 20% (quantile 80) of cells based on feature expression (TRUE) and gray indicating the remaining cells (FALSE). D, Heatmaps of in vitro APK CTOs and AKTP MTOs treated with vehicle or RMC-9945 for 48 hours, hierarchically clustered using the Ward D2 method based on keratinization gene list. E, Representative example of hematoxylin and eosin (H&E) staining on liver metastases treated with vehicle or RMC-9945 for 11 days. Scale bar, 50 μm. F, Representative example of E-cadherin immunofluorescence on liver metastases treated with vehicle or RMC-9945. Top scale bar, 100 μm. Bottom scale bar, 20 μm. G–I, Volcano plot showing expression differences of the EpiHR signature ( G ), the basal pancreatic signature ( H ), and keratinization genes ( I ) between samples with and without driver mutations in individual oncogenes and tumor-suppressor genes from the COAD TCGA patient cohort ( n = 520 patients). The difference of median values (x axis) versus P values (Wilcoxon rank-sum test; y axis) are shown. J, Volcano plot of differential expression of samples with and without mutations in the KRAS signaling pathway. Genes of interest are highlighted. FC, fold change.

Year:

2026

KRAS G12D inhibition enforces a Lgr5 + ISC-like transcriptional program in liver metastases. A, Experimental setup of RMC-9945 treatment of liver metastases. Treatment started at day 15, 21, or 25 after inoculation of liver metastases implanted in the spleen (IS) of C57BL/6J mice and continued for 11 days. B, Longitudinal intravital bioluminescence quantification of AKTP MTOs treated with vehicle or RMC-9945. C, Treatment from day 15, day 21, and day 25 of established liver metastases (LiM) generated by injecting AKTP MTOs in the spleen of C57BL/6J mice. Number of liver metastases. Vehicle n = 5 mice, D15 n = 7, D21 n = 8, and D25 = 8. Mean ± SEM; P values are derived from ANOVA followed by two-sided Dunnett tests. D, UMAP visualization of scRNA-seq ( n = 11,410) showing vehicle-treated (gray) and RMC-9945–treated (green) cells. Mice were treated from day 21 to day 26 (6 days), and liver metastasis dissected. E, UMAP projection with data points colored by Louvain clusters (resolution 0.6), in which each cluster is represented in a unique color to emphasize the dataset’s underlying structure. F, Bar plot showing the frequency distribution of cells in the vehicle and RMC-9945 groups within each cluster, ordered by their association with CSC, intermediate, or HRC states. Percentages represent the proportion of cells in each group per cluster. G and H, UMAP visualization and violin plot showing HRC (EpiHR + ) cells ( G ) and the expression (MAGIC values) of the Emp1 gene ( H ). I and J, UMAP visualization and violin plot showing CSCs ( Lgr5 + ISC-like) and the expression (MAGIC values) of the Lgr5 gene ( J ). MAGIC, Markov Affinity-based Graph Imputation of Cells. K, UMAP visualization and violin plot showing proliferative cells. Gene signatures used for the analysis are detailed in Supplementary Table S1. In the UMAP visualization, black indicates the top 20% (quantile 80) of cells based on feature expression (true) and gray indicates the remaining cells (false). The gene expression UMAP is split by the vehicle and RMC-9945 groups. L, Treatment from day 21 of established liver metastases (LiM) generated by injecting AKTP Emp1-Tom MTOs in the spleen of C57BL/6J mice. M, Percentage of Lgr5 mRNA spots detected by RNAscope on the total cell number detected in each metastasis. Each dot represents one metastasis. Vehicle n = 56, RMC-9945 n = 71. Mean ± SEM; P values are derived from unpaired t test. N, Representative example of Lgr5 mRNA FISH combined with tdTomato immunofluorescence on liver metastases sections. Scale bar, 400 μm. O, Treatment from day 15 of established liver metastases (LiM) generated by injecting AKTP MTOs Emp1-Tom in the spleen of C57BL/6J mice. P, Percentage of Lgr5 mRNA spots detected by RNAscope on the total cell number detected in each metastasis. Each dot represents one metastasis. Vehicle n = 95, RMC-9945 n = 87. Mean ± SEM; P values are derived from unpaired t test. Q, Representative example of Lgr5 mRNA FISH combined with tdTomato immunofluorescence on liver metastases sections. Scale bar, 100 μm.

Year:

2026

Supplementary Figures S1-S14 related to the manuscript "A plastic EMP1 + to LGR5 + cell state conversion as a bypass to KRAS-G12D pharmacological inhibition in metastatic colorectal cancer"

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2022

Collaborators (20)

Alberto Munoz

Research Professor

Spanish National Research Council (CSIC)

SPAIN
View details

Sunil Kumar

Imperial College London

UNITED KINGDOM
View details

Fabian Fröhlich

Group Leader

The Francis Crick Institute

UNITED KINGDOM
View details

Andrea Serio

Group Leader (Seconded)

King’s College London

UNITED KINGDOM
View details

Rebecca Lee

The University of Manchester

UNITED KINGDOM
View details

Johannes Zuber

Senior Group Leader

Research Institute of Molecular Pathology

AUSTRIA
View details

MARTA SEVILLANO

Institute for Research in Biomedicine

SPAIN
View details

Iain McNeish

Imperial College London

UNITED KINGDOM
View details

Morag Park

McGill University

CANADA
View details

Eduard Batlle

ICREA Research professor / Head of the Colorectal Cancer Lab / Chairman of IRB’s Cancer Science Programme

Institut de Recerca Biomèdica

SPAIN
View details

Hector Palmer

Director

Vall d'Hebron Institute of Oncology

SPAIN
View details

James MacRae

Head of metabolomics

The Francis Crick Institute

UNITED KINGDOM
View details

Julien Colombelli

Head

Institute for Research in Biomedicine

SPAIN
View details

Joshua B. Edel

Imperial College London

UNITED KINGDOM
View details

Aleksandar Ivanov

Imperial College London

UNITED KINGDOM
View details

James Briscoe

The Francis Crick Institute

UNITED KINGDOM
View details

Antonio Barbáchano Becerril

Científico Titular at CNB-CSIC

Consejo Superior de Investigaciones Cientificas

SPAIN
View details

P. M. W. French

Professor

Imperial College London

UNITED KINGDOM
View details

Erik Sahai

The Francis Crick Institute

UNITED KINGDOM
View details

Rachael Natrajan

Team Leader

Institute of Cancer Research

UNITED KINGDOM
View details